Skip Navigation


Brain Advance Access originally published online on November 4, 2005
Brain 2006 129(1):189-199; doi:10.1093/brain/awh645
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
129/1/189    most recent
awh645v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sairanen, T.
Right arrow Articles by Lindsberg, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sairanen, T.
Right arrow Articles by Lindsberg, P. J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2005). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Apoptosis dominant in the periinfarct area of human ischaemic stroke—a possible target of antiapoptotic treatments

Tiina Sairanen1,2, Marja-Liisa Karjalainen-Lindsberg1,3, Anders Paetau3, Petra Ijäs1,2 and Perttu J. Lindsberg1,2

1 Neuroscience Program, Biomedicum Helsinki, 2 Departments of Neurology and 3 Pathology, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland

* Correspondence to: Dr Tiina Sairanen, Department of Neurology, Helsinki University Central Hospital, PB 340, FIN-00029 HUS, Helsinki, Finland E-mail: tiina.sairanen{at}hus.fi

Animal experiments have suggested that apoptotic programmed cell death is responsible for an important portion of the delayed ischaemic brain damage. Antiapoptotic signalling through erythropoietin (EPO) binding to its receptor (EPOR) is triggered by systemic or local hypoxia and may exist in the post-ischaemic brain, and a neuroprotective effect by EPO was described recently and proposed for clinical stroke treatment. The objective of the study was to determine whether apoptosis occurs in human ischaemic stroke and to describe its topographical distribution. An autopsy cohort consisting of 13 cases of fatal ischaemic stroke (symptom duration from 15 h to 18 days) treated at the Department of Neurology, Helsinki University Central Hospital and 3 controls were studied. DNA damage was investigated by immunofluorescent TUNEL-labelling in combination with apoptotic cell morphology and by visualization of a major signalling system of apoptosis, Fas–FasL (Fas-ligand), by the immunoperoxidase technique. The relationship of EPO and EPOR in the face of TUNEL-labelled and necrotic cell death was co-registered in human cerebral neurons undergoing different stages of ischaemic change. TUNEL-labelled cells with apoptotic morphology were disproportionately more frequent, 148% (30) [mean (SE)] in the periinfarct versus 97% (22) in the core, as percentage of the cells in the contralateral hemisphere (P = 0.027). The apoptotic cell percentage reached up to 26% (2) of all cells in periinfarct area. A linear correlation was found for Fas and its counterpart FasL expression (rS = 0.774, P < 0.001). Ischaemia induced widespread neuronal expression of EPOR, which was inversely related to the severity of ischaemic neuronal necrosis (P < 0.05). To conclude, these data verify the predominance of apoptosis in the periphery of human ischaemic infarctions. Fas and FasL were linearly overexpressed supporting that this ‘death-receptor’ complex may promote the completion of cell death. Increased EPO signalling may be a cellular response for survival in less severely damaged areas. These results support antiapoptotic therapies against delayed neuronal cell death in human ischaemic stroke.

Key Words: apoptosis; ischaemic stroke; human; pathophysiology; immunohistochemistry

Abbreviations: Ab = antibody; DAPI = 4',6-diamino-2-phenylindole; EPO = erythropoietin; EPOR = erythropoietin receptor; FasL = Fas ligand; GFAP = astrocyte marker glial fibrillary acidic protein; MoAb = monoclonal antibody; NF-200 = neurofilament-200 kDa; Pc = polyclonal antibody; TUNEL = terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labelling

Received April 25, 2005. Revised August 17, 2005. Accepted August 30, 2005.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
StrokeHome page
P. Delgado, E. Cuadrado, A. Rosell, J. Alvarez-Sabin, A. Ortega-Aznar, M. Hernandez-Guillamon, A. Penalba, C. A. Molina, and J. Montaner
Fas System Activation in Perihematomal Areas After Spontaneous Intracerebral Hemorrhage
Stroke, June 1, 2008; 39(6): 1730 - 1734.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. S. Lee, J. S. Lee, and J. Y. Lee
Prevention of Erythropoietin-Associated Hypertension
Hypertension, August 1, 2007; 50(2): 439 - 445.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
A. Viswanathan, F. Gray, M.-G. Bousser, M. Baudrimont, and H. Chabriat
Cortical Neuronal Apoptosis in CADASIL
Stroke, November 1, 2006; 37(11): 2690 - 2695.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.